The DOI matches its OpenAlex record; 28 of the 28 references it cites were found in a registry or an index.
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
Abstract
It has been suggested that vitamin D deficiency may promote prostate cancer, although the mechanism is not understood. In this study three human prostate carcinoma cell lines, LNCaP, DU-145, and PC-3, were examined both for the presence of specific 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] receptors (VDRs) and also employed to study the effects of hormone on cell proliferation and differentiation. Ligand binding experiments demonstrated classical VDR in all three cell lines examined with an apparent dissociation constant of 7.5, 5.4, and 6.3 x 10(-11) M for LNCaP, DU-145, and PC-3 cells, respectively. Corresponding binding capacity for the three prostate carcinoma cell lines were 27, 31, and 78 fmol/mg protein, respectively. The presence of VDR in the three cell lines was also confirmed by immunocytochemistry. In addition, one major 4.6-kilobase messenger RNA transcript hybridizing with a specific human VDR complementary DNA probe was identified in all three cell lines. Interestingly, both DU-145 and PC-3 but not LNCaP cell lines exhibited 1,25(OH)2D3-stimulated induction of 24-hydroxylase messenger RNA employed as a marker of 1,25(OH)2D3 action. Physiological levels of 1,25(OH)2D3 dramatically inhibited proliferation of the LNCaP and PC-3 cell lines. However, in spite of the presence of high affinity VDR, proliferation of DU-145 cells was not inhibited by 1,25(OH)2D3 at the doses tested. Treatment with 1,25(OH)2D3 caused a dose-dependent stimulation of prostate-specific antigen secretion by LNCaP cells. In conclusion, these results demonstrate that these three human prostate carcinoma cell lines all possess specific VDR and that 1,25(OH)2D3 treatment can elicit both an antiproliferative and a differentiating action on these cancer cells. The findings lend support to the hypothesis that vitamin D might exert beneficial actions on prostate cancer risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Purification of Mouse Immunoglobulin Heavy‐Chain Messenger RNAs from Total Myeloma Tumor RNA
AUFFRAY, C., & ROUGEON, F. (1980) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1980.tb06030.x · Cited by 2,627
Cloning and expression of full-length cDNA encoding human vitamin D receptor.
Baker, A. R., McDonnell, D. P., Hughes, M., Crisp, T. M., Mangelsdorf, D. J., Haussler, M. R., Pike, J. W., Shine, J., & O'Malley, B. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3294 · Cited by 959
NORMAN, A. W., ROTH, J., & ORCI, L. (1982) · Endocrine Reviews · doi:10.1210/edrv-3-4-331 · Cited by 703
SERUM 25-HYDROXYVITAMIN D AND COLON CANCER: EIGHT-YEAR PROSPECTIVE STUDY
Garland, C., Garland, F., Shaw, E., Comstock, G., Helsing, K., & Gorham, E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91789-3 · Cited by 678
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
Schwartz, G. G., & Hulka, B. S. (1990) · PubMed · Cited by 508
Repression of c- fos Transcription and an Altered Genetic Program in Senescent Human Fibroblasts
Seshadri, T., & Campisi, J. (1990) · Science · doi:10.1126/science.2104680 · Cited by 481
Kerner, S. A., Scott, R. A., & Pike, J. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4455 · Cited by 405
Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study.
Hsing, A. W., McLaughlin, J. K., Schuman, L. M., Bjelke, E., Gridley, G., Wacholder, S., Chien, H. T. C., & Blot, W. J. (1990) · PubMed · Cited by 348
Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.
Eisman, J. A., Barkla, D. H., & Tutton, P. J. M. (1987) · PubMed · Cited by 309
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
The role of vitamin D in reducing cancer risk and progression
Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E., & Feldman, B. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3691 · Cited by 1,311
Self-citationNoncalcemic Actions of Vitamin D Receptor Ligands
Nagpal, S., Na, S., & Rathnachalam, R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0002 · Cited by 961
Ingles, S. A., Ross, R. K., Yu, M. C., Haile, R. W., Irvine, R. A., La Pera, G., & Coetzee, G. A. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.166 · Cited by 583
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
Ahonen, M. H., Tenkanen, L., Teppo, L., Hakama, M., & Tuohimaa, P. (2000) · Cancer Causes & Control · doi:10.1023/a:1008923802001 · Cited by 494
Metadata
- Authors
- Skowroński, R., Peehl, D. M., & Feldman, D. I.
- Venue
- Endocrinology
- Publisher
- Oxford University Press
- Published
- 1993-05-01
- Volume
- 132
- Issue
- 5
- Pages
- 1952-1960
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W1986527803
- Cited by
- 494
- References
- 28
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. https://app.cochat.ai/papers/10.1210/en.132.5.1952
- The paper
- Skowroński, R., Peehl, D. M., & Feldman, D. I. (1993). Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. https://doi.org/10.1210/en.132.5.1952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.